

# Differential DNA Methylation Profiles of Infants Exposed to Maternal Asthma During Pregnancy

Lakshitha P. Gunawardhana, B.Biotech,<sup>1</sup> Katherine J. Baines, PhD,<sup>1\*</sup> Joerg Mattes, MBBS, PhD,<sup>1,2</sup> Vanessa E. Murphy, PhD,<sup>1</sup> Jodie L. Simpson, PhD,<sup>1</sup> and Peter G. Gibson, MBBS, PhD<sup>1,2,3</sup>

**Summary.** Background: Asthma is a complex disease that involves both genetic factors and environmental exposures. Aberrant epigenetic modifications, such as DNA methylation, may be important in asthma development. Fetal exposure to maternal asthma during critical periods of in utero development may lead to epigenetic alterations that predispose infants to a greater risk of developing asthma themselves. We investigated alterations in the DNA methylation profile of peripheral blood from infants exposed to maternal asthma during pregnancy. Methods: Peripheral blood was collected from 12-month-old infants born to women with ( $n = 25$ ) and without ( $n = 15$ ) doctor diagnosed asthma during pregnancy. Genomic DNA was extracted, bisulfite converted, and hybridized to Infinium Methylation 27 arrays (Illumina), containing over 27,000 CpGs from 14,495 genes. CpG loci in only autosomal genes were classified as differentially methylated at the 99% level ( $P < 0.01$ , IDiffScore  $> 22$  and delta beta  $> 0.06$ ). Results: There were 70 CpG loci, corresponding to 67 genes that were significantly differentially methylated. Twelve CpG loci (11 genes) showed greater than 10% comparative difference in DNA methylation, including hypermethylated loci of *FAM181A*, *MRI1*, *PIWIL1*, *CHFR*, *DEFA1*, *MRPL28*, *AURKA*, and hypomethylated loci of *NALP1L5*, *MAP8KIP3*, *ACAT2*, and *PM20D1* in maternal asthma. Methylation of *MAP8KIP3* was significantly negatively correlated with maternal blood eosinophils ( $r = -0.38$ ;  $P = 0.022$ ), maternal eNO ( $r = -0.44$ ;  $P = 0.005$ ), and maternal serum total IgE ( $r = -0.39$ ,  $P = 0.015$ ). Methylation of *AURKA* negatively correlated with maternal hemoglobin ( $r = -0.43$ ;  $P = 0.008$ ), infants height ( $r = -0.51$ ;  $P < 0.001$ ) and weight ( $r = -0.36$ ;  $P = 0.021$ ). Methylation of *PM20D1* was lower in infants born to mothers with asthma on inhaled corticosteroid treatment. Methylation of *PM20D1* was lower and *MRI1* was higher in infants born to atopic mothers without asthma. Conclusions: In an Australian study population, exposure to maternal asthma during pregnancy is associated with differential methylation profiles of infants' peripheral blood DNA, which may act as risk factors for future asthma development. **Pediatr Pulmonol.**

© 2013 Wiley Periodicals, Inc.

**Key words:** maternal asthma; DNA methylation; pregnancy; CpG loci; Illumina Infinium.

**Funding source:** Asthma Foundation NSW, Australia, The University of Newcastle and Hunter Medical Research Institute

## INTRODUCTION

Asthma is a complex polygenic disease that results from genetic susceptibility and environmental exposure. This interaction promotes the chronic and heterogeneous inflammatory response and the airway hyperresponsiveness that characterize asthma. A key mechanism that

underpins how environmental exposures modulate gene expression is via methylation of cytosine of the CpG dinucleotide (DNA methylation) in the gene-promoter regions, a well characterized and long-lasting epigenetic phenomenon. Therefore, these epigenetic alterations independently or together with genetic factors may underpin asthma susceptibility. This susceptibility occurs

<sup>1</sup>Priority Research Centre for Asthma and Respiratory Disease, Hunter Medical Research Institute, The University of Newcastle, Sydney, NSW, Australia.

<sup>2</sup>Department of Respiratory & Sleep Medicine, HMRI, John Hunter Hospital, New Lambton, NSW, Australia.

<sup>3</sup>Woolcock Institute of Medical Research, Sydney, NSW, Australia.

Conflict of interest: The authors have no conflicts of interest to declare.

\*Correspondence to: Katherine J. Baines, PhD, Level 2 West, Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton Heights, NSW 2310, Australia. E-mail: katherine.baines@newcastle.edu.au

Received 1 March 2013; Revised 29 July 2013; Accepted 13 August 2013.

DOI 10.1002/ppul.22930

Published online in Wiley Online Library (wileyonlinelibrary.com).

from conception since the intra-uterine microenvironment is pivotal in sustaining fetal development as well as re-shaping of the epigenome. Certain exposures during pregnancy such as adverse nutrition, smoking and maternal diseases are known to effect both fetal outcomes such as still births, fetal growth restriction and predisposition to variety of diseases.<sup>1–3</sup> Asthma is one of the most common medical illnesses to complicate pregnancy, with prevalence of 12% in Australia.<sup>4</sup> It is associated with both poor pregnancy outcomes<sup>5–7</sup> and with the development of childhood asthma. For example, maternal asthma has been found to be the strongest predictor of childhood asthma<sup>8</sup> and in addition, poor control of maternal asthma during pregnancy is associated with a further increased risk of childhood asthma.<sup>9</sup>

The mechanisms by which maternal asthma contributes to these neonatal adversities include a direct effect of an altered cytokine environment induced by asthma, including reduced pro-inflammatory cytokine responses to immune challenge.<sup>10</sup> Other possibilities are that exposures associated with maternal asthma, such as the use of medications including corticosteroids and the effects of exacerbations during pregnancy may play a role.

Studies based on phenotypically measurable outcomes such as birth weight and infant wheezing therefore show that maternal asthma, its complications and its treatment during pregnancy can contribute to adverse outcomes for the infant. The intermediate stages that mediate these changes have not been defined. Maternal asthma likely induces modifications to the intra-uterine environment which could influence the developing epigenome of the infant, either causing immediate phenotypic manifestations, such as alterations to infant weight, or other silent epigenetic alterations that become active later in life, leading to increased disease susceptibility. Although it has been suspected that epigenetic changes may play a vital role in these effects, there have been no studies investigating epigenetic effects of maternal asthma during pregnancy.

Our objective was therefore to investigate alterations in the peripheral blood DNA methylation profile of 12-month-old infants due to maternal asthma during pregnancy and relate these to phenotypic change in the infants, as well as exposure characteristics in the mother. We hypothesized that maternal asthma would result in characteristic changes in the DNA methylation profile in peripheral blood of infants.

## METHODS

### Study Design and Participants

The study population consisted of a cohort of infants (n = 40) born to women who participated in the Managing Asthma in Pregnancy Study<sup>11</sup> and a cohort study of viral infection in pregnancy, and were prospectively followed in infancy (the Growing Into Asthma birth cohort).

Pregnant women with and without asthma were initially recruited between 12 and 20 weeks of gestation and had monthly clinical assessments of symptoms, lung function, and Fraction of exhaled nitric oxide (FeNO) (Ecomedics CLD 88 sp; Duernten, Switzerland) until delivery. Asthma diagnosis was confirmed by a respiratory physician (PGG) and women with current (past year) symptoms and/or medication use were enrolled.

Detailed clinical assessments were performed on infants at birth, 6 months and at 12 months of age by a respiratory pediatrician (J.M.). Additional information such as respiratory and allergy symptoms, growth and general health were obtained by a validated questionnaire<sup>12</sup> and by interviewing a parent/guardian. Mothers and their infants were excluded from our analysis if they were current smokers or had significant smoke exposure as determined by detection of urinary cotinine (NicAlert Urine Screen; Accutest, Encino, CA). A sample of blood was collected from the infants at age of 12 months. The study was approved by the Hunter New England Health and the University of Newcastle Human Research Ethics Committees.

### DNA Extraction and Bisulfide Conversion

Genomic DNA was purified from fresh frozen aliquots of whole blood (200 µl) using the DNAeasy Mini Kit (Qiagen, Victoria, Australia), and quantified by PicoGreen assay (Life Technologies, Victoria, Australia) following manufacturer's recommendations. A Nano drop 2000 (Thermo Fisher Scientific, Victoria, Australia) was used for assessment of DNA quality (the 260 nm/280 nm optical density ratio of 1.7–2.1 was deemed acceptable). In all, 500 ng of DNA was treated with sodium bisulfite using the EZ DNA Methylation Gold Kit (Zymo Research, Orange, CA) according to the manufacturer's recommended procedure adapted for Illumina's Infinium methylation analysis.

### Genome-Wide Methylation Assay

DNA methylation analysis was conducted using the Illumina Infinium Human Methylation27 Bead Chip (Illumina, San Diego, CA). These arrays facilitate high-throughput processing and analysis of DNA methylation at genome-wide scale by interrogating over 27,000 highly informative CpG di-nucleotides, spanning 14,495 genes. The assay is highly accurate and powerful in detecting the methylation status of queried CpG loci<sup>13,14</sup> and has extremely high reproducibility.<sup>13</sup> To assess DNA methylation, we used the standard Illumina protocols. In brief, the bisulfite converted samples were whole genome amplified and the amplified products were then fragmented by an endpoint enzymatic process. The fragmented DNA was purified and hybridized to Infinium Human Methylation 27 arrays. During hybridization, the

amplified and fragmented DNA samples anneal to locus specific DNA oligomers residing on the bead chips. Single base extension reaction, washing and staining were then carried out using a TECAN Te-Flow chamber. The stained arrays were assessed for fluorescence intensities at the methylated and unmethylated bead sites using Illumina BeadArray Reader (Illumina).

### EpiTect Methyl II DNA Methylation qPCR Primer Assay

To further validate our findings from the Illumina arrays, the EpiTect methyl II System (Qiagen, Australia) was employed to measure the methylation of PIWIL-1.

Genomic DNA (250 ng) was digested using the EpiTect methyl II DNA restriction Kit (Qiagen, Hilden, Australia) according to the manufacturer's instructions. The RT<sup>2</sup> SYBR Green ROX qPCR Mastermix and the validated methyl II assay for PIWIL-1 (EPHS103593-1A) were combined and real-time PCR was performed using the ABI 7500 system (Applied Biosystems, Foster City, CA) according to manufacturer's instructions.

### Data Analysis

Raw fluorescence data were processed using the Illumina methylation module (version 1.0.5) of the GenomeStudio<sup>TM</sup> software (version 1.0.2.20706). The  $\beta$  value was used to estimate the methylation level of the CpG locus by calculating the ratio of intensities between methylated and unmethylated alleles ( $1 > \text{Average } \beta > 0$  represents fully methylated to un-methylated alleles). A quality analysis was performed on each array in relation to bisulfide conversion efficiency, hybridization efficiency and specificity, single base extension rate, target removal, staining for negative controls and staining for non-polymorphic probes. Prior to statistical analysis, the detection  $P$  value of 0.05 was used to eliminate CpGs that were poorly detected. In order to eliminate systematic differences between males and females, all CpGs residing on X and Y chromosomes were dropped from the analysis.

GenomeStudio software generates a DiffScore value to illustrate difference between groups, and is closely related to statistical  $P$  values. The DiffScore, takes into account background noise and sample variability.<sup>15</sup> For a CpG locus to be differentially methylated it must satisfy two criteria, (1) Absolute DiffScore calculated using the Illumina custom model adjusted for multiple comparisons using the Benjamini and Hochberg false discovery rate must be greater than 22 (equivalent to adjusted  $P < 0.01$ ), and (2) the degree of difference measured by the change in  $\beta$  value ( $\Delta\beta$ ) is greater than 0.06 (corresponding to an average of 6% or greater methylation difference). This statistical model bears the assumption that the methylation value  $\beta$  is normally distributed among biological replicates corresponding to a set of biological conditions.

The outcome, DiffScore of a probe is computed as:

$$\text{DiffScore} = 10\text{sign}(\beta_{\text{asthma}} - \beta_{\text{normal}}) \log_{10} P$$

$$\text{Delta } \beta = (\beta_{\text{asthma}} - \beta_{\text{normal}})$$

Illumina custom error model and DiffScore has been described previously.<sup>16</sup> For the EpiTect Methyl II qPCR, Cycle threshold (Ct) values were used to calculate the percentages of methylation according to the instructions from the manufacturer (Qiagen). To investigate which biological functions of genes are significantly enriched, a gene ontology analysis was performed using PANTHER.<sup>17</sup>

Further statistical analysis was performed using PRISM version 5 (GraphPad Software, San Diego, CA) and Stata 11 (Stata Corp., College Station, TX). Parametric and non-parametric data are presented as means (standard deviation) and medians (quartile 1, quartile 3) unless otherwise stated. Categorical data were compared using the  $\chi^2$  test or Fisher's exact test. For comparison of two continuous variables the two-sample Student's  $t$  test was used, and for parametric data the Mann-Whitney  $U$  test was used. Multiple comparisons of continuous variables were analyzed using one-way ANOVA with Bonferroni correction for parametric data, and Kruskal-Wallis test for non-parametric data. Associations of methylation levels of individual genes were tested using Pearson correlation for parametric data and Spearman correlation for non-parametric data. Associations were first investigated using a correlation matrix, following up the significant results using a scatter plot to visualize the distribution of the data. Statistical significance was defined as  $P < 0.05$ .

## RESULTS

### Clinical Features

The clinical characteristics of the infants and their mothers are detailed in Table 1. Although infants had normal anthropometry at birth, at 12 months, the average height of infants born to mothers with asthma was significantly lower than infants born to mothers without asthma. The mothers with asthma had elevated fractional exhaled nitric oxide (FeNO) as recorded at the first visit (gestation weeks 16–20) compared to mothers without asthma. More than half (64%,  $n = 14$ ) of the asthmatics were taking inhaled corticosteroids (ICS), and 48% of women had one or more asthma exacerbations (defined by hospitalization, emergency department visit, course of oral steroid or unscheduled doctor visit) during their pregnancy. A higher proportion of women were atopic in the maternal asthma group (80%) compared to only 40% of non-asthmatic women (Table 1). Significantly increased total IgE and reduced red cell count was observed in mothers with asthma, as well as a trend for lower

**TABLE 1—Maternal and Infant Characteristics**

|                                                 | Maternal asthma | Non-maternal asthma | P-Value <sup>1</sup> |
|-------------------------------------------------|-----------------|---------------------|----------------------|
| N                                               | 25              | 15                  |                      |
| Infant characteristics                          |                 |                     |                      |
| Gestational age (weeks)                         | 39.0            | 39.4                | 0.374                |
| Male, gender, n (%)                             | 12 (48%)        | 7 (47%)             | 1.000                |
| Birth weight, kg, mean (SD)                     | 3.4 (0.43)      | 3.5 (0.55)          | 0.392                |
| Birth length, cm, mean (SD)                     | 50.6 (2.53)     | 51.7 (2.55)         | 0.238                |
| Head circumference, cm, mean(SD)                | 34.4 (1.40)     | 34.7 (1.55)         | 0.567                |
| Weight 12 months, kg, mean (SD)                 | 1.0 (1.44)      | 10.4 (0.88)         | 0.342                |
| Height 12 months, cm, mean (SD)                 | 75.9 (3.42)     | 78.3 (2.37)         | 0.023                |
| Head circumference 12 months, cm, mean (SD)     | 46.6 (1.59)     | 46.4 (1.01)         | 0.652                |
| Wheeze, n (%yes)                                | 11 (44%)        | 3 (20%)             | 0.177                |
| Bronchiolitis, n (%yes)                         | 5 (20%)         | 5 (33%)             | 0.457                |
| Eczema, n (%yes)                                | 4/24 (17%)      | 4 (30%)             | 0.444                |
| β <sub>2</sub> agonists                         | 2 (8%)          | 1 (7%)              | 1.000                |
| ICS and β <sub>2</sub> agonists                 | 1 (4%)          | 0 (0%)              | 1.000                |
| OCS oral corticosteroid                         | 3 (12%)         | 0 (0%)              | 0.279                |
| Maternal characteristics                        |                 |                     |                      |
| Age of mother, years (mean, SD)                 | 30.4 (5.59)     | 31.0 (4.58)         | 0.707                |
| %FEV1 (mean, SD)                                | 95.1 (14.25)    | 104.3 (12.58)       | 0.056                |
| %FVC (mean, SD)                                 | 103.2 (15.52)   | 112.7 (14.11)       | 0.075                |
| %FEV1/FVC (mean, SD)                            | 0.9 (0.11)      | 0.9 (0.44)          | 0.999                |
| ACQ (mean, SD) <sup>2</sup>                     | 1.15 (0.89)     | N/A                 |                      |
| FeNO ppb median (Q1–Q3)                         | 19.5 (10.8–33)  | 8.8 (5.8–13.1)      | 0.003                |
| Inhaled corticosteroids, n, (%Yes) <sup>3</sup> | 14 (64%)        | N/A                 |                      |
| Maternal atopy, n (%yes)                        | 20 (80%)        | 40% (6)             | 0.014                |
| Exacerbation, n, (%)                            | 12 (48%)        | N/A                 |                      |
| Total IgE, median (Q1–Q3)                       | 150 (29–279)    | 47 (12–107)         | 0.030                |

<sup>1</sup>Fisher's exact test was used for categorical variables.<sup>2</sup>Maternal ACQ from the first visit.<sup>3</sup>Based on consistent ICS use throughout pregnancy.

maternal hemoglobin levels compared to mothers without asthma (Table 2).

### Differential DNA Methylation in Peripheral Blood of Infants Due to Maternal Asthma

The differential methylation status across 27,578 CpG dinucleotides was tested. Pre-processing identified 69 loci

with poor detection and these were dropped from the analysis. Only autosomal loci were selected from the remaining and 26,475 loci were analyzed for differential methylation. There were 159 CpG loci that were significantly differentially methylated (DiffScore >22,  $P < 0.01$ ) in the peripheral blood of infants born to mothers with asthma compared to mothers without asthma. Seventy of these differentially methylated CpG

**TABLE 2—Maternal and Infant Blood Cell Count**

|                                                 | Maternal asthma | Non-maternal asthma | P-Value <sup>1</sup> |
|-------------------------------------------------|-----------------|---------------------|----------------------|
| Infants' cell counts <sup>1</sup>               |                 |                     |                      |
| Red cell, 10 <sup>12</sup> /L, mean (SD)        | 4.4 (0.28)      | 4.3 (0.21)          | 0.217                |
| Eosinophil, 10 <sup>9</sup> /L, mean (SD)       | 0.3 (0.25)      | 0.3 (0.22)          | 0.786                |
| Neutrophil, 10 <sup>9</sup> /L, mean (SD)       | 3.3 (1.69)      | 3.9 (2.55)          | 0.438                |
| Lymphocytes, 10 <sup>9</sup> /L, mean (SD)      | 6.2 (1.82)      | 6.9 (2.39)          | 0.325                |
| Maternal cell counts <sup>2</sup>               |                 |                     |                      |
| Red cell (10 <sup>12</sup> /L), mean (SD)       | 3.8 (0.28)      | 4.0 (0.28)          | 0.032                |
| Eosinophil (10 <sup>9</sup> /L), median (Q1–Q3) | 0.2 (0.08–0.31) | 0.1 (0.04–0.12)     | 0.107                |
| Neutrophil (10 <sup>9</sup> /L), mean (SD)      | 7.6 (1.76)      | 7.5 (1.83)          | 0.863                |
| Lymphocytes (10 <sup>9</sup> /L), mean (SD)     | 1.8 (0.33)      | 1.8 (0.35)          | 0.809                |
| Hemoglobin (g/L), mean (SD)                     | 116.3 (8.68)    | 121 (7.80)          | 0.055                |

<sup>1</sup>Infant's cell counts performed at 12 months of age.<sup>2</sup>Maternal cell counts performed at each clinic visit during their pregnancy and averages were taken. Mean and standard deviation noted when data normally distributed (t-test) and otherwise median with interquartile range (Mann–Whitney test).

loci had a  $\Delta\beta$  of greater than 0.06, and this corresponded to 68 genes. The 68 differentially methylated genes are listed in supplementary Table S1 in the supplementary material. Of these 70 CpG loci, 46 had increased methylation (hypermethylation) associated with maternal asthma, whilst 24 had a decreased methylation (hypomethylation) associated with maternal asthma. The most significantly differentially methylated genes with the greatest change in  $\Delta\beta$  ( $>0.1$  or 10% methylation) are listed in Table 3. Of those CpG loci presented in Table 3, seven CpGs had increased methylation (hypermethylation) and four had decreased methylation (hypomethylation). *NAPIL5* is a paternally imprinted gene<sup>18</sup> and consequently its methylation status cannot be attributed to maternal factors. The distribution of the methylation for 8 of these loci is presented in Figure 1.

The methylation status of the *PIWIL-1* locus as determined by the Epitect methyl II qPCR was highly correlated with the outcomes of the arrays ( $r=0.86$ ,  $P<0.0001$ ) and further confirmed the observed difference between the groups ( $P=0.002$ ; Fig. 4).

To investigate significantly enriched gene ontologies, the list of 68 differentially methylated genes were mapped to PANTHER biological processes, molecular functions and cellular components. Of the 68 genes, 61 were mapped to the PANTHER categories. There were five biological processes and three molecular functions that were significantly enriched ( $P<0.02$  detection rate versus the whole genome), shown in Table 4.

### Effects of Asthma Medication and Atopy

The effects of maternal ICS use during pregnancy and maternal atopy on the methylation level of the differentially methylated genes (shown in Table 3) were further investigated. Methylation of the CpG locus of *PM20D1* was the only gene significantly associated with ICS treatment for maternal asthma during pregnancy ( $P=0.039$ ; Fig. 2A) and maternal atopy ( $P=0.0031$ ; Fig. 2B).

### Clinical Associations

The relevance of the changes in peripheral blood DNA methylation of infants associated with maternal asthma during pregnancy was investigated regarding their relationship to clinical parameters and peripheral blood cell counts of the mother and the infant. Interestingly, methylation of *MAPK8IP3* was significantly negatively correlated with maternal eosinophils (Fig. 3A), maternal FeNO (Fig. 3B), maternal serum total IgE (Fig. 3C). However the methylation of this locus not associated with infant's blood eosinophil count ( $r=0.04$ ,  $P=0.82$ ). Methylation of *PM20D1* was also negatively correlated with maternal serum total IgE [cg14893161:  $r=-0.39$ ;  $P=0.01$ , cg14159672:  $r=-0.42$ ,  $P=0.009$ ]. The level

TABLE 3—Differentially Methylated CpG Loci in Infants Born to Mothers With Asthma

| Illumina ID | Symbol          | Hugo gene name                                                                | $\beta$ , Mean (SD) |                 | $\Delta\beta$ , Mean (SD) | IDiffScore1 | P-Value  | Chromosome | CpG site map info (nucleotide bases to transcription start site) |
|-------------|-----------------|-------------------------------------------------------------------------------|---------------------|-----------------|---------------------------|-------------|----------|------------|------------------------------------------------------------------|
|             |                 |                                                                               | Non-maternal asthma | Maternal asthma |                           |             |          |            |                                                                  |
| cg20022541  | <i>FAM181A</i>  | Family with sequence similarity 181, member A                                 | 0.54 (0.288)        | 0.71 (0.241)    | -0.16 (0.369)             | 221.8       | 6.61E-23 | 14         | 93455148 (137)                                                   |
| cg16474696  | <i>MRII</i>     | Methylthioribose-1-phosphate isomerase 1                                      | 0.25 (0.231)        | 0.41 (0.301)    | -0.16 (0.379)             | 223.6       | 4.37E-23 | 19         | 13736014 (332)                                                   |
| cg13861644  | <i>PIWIL1</i>   | Piwi-like RNA mediated gene silencing 1                                       | 0.66 (0.176)        | 0.82 (0.111)    | -0.15 (0.208)             | 241.8       | 6.61E-25 | 12         | 129388239 (328)                                                  |
| cg17003970  | <i>CHFR</i>     | Checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase | 0.67 (0.195)        | 0.81 (0.036)    | -0.14 (0.198)             | 225.3       | 2.95E-23 | 12         | 131945934 (—)                                                    |
| cg17267907  | <i>DEFA1</i>    | Defensin, alpha 1                                                             | 0.66 (0.224)        | 0.77 (0.131)    | -0.12 (0.259)             | 119.3       | 1.17E-12 | 8          | 6825434 (422)                                                    |
| cg12437481  | <i>MRPL28</i>   | Mitochondrial ribosomal protein L28                                           | 0.57 (0.291)        | 0.68 (0.226)    | -0.10 (0.368)             | 71.0        | 7.94E-08 | 16         | 360113 (428)                                                     |
| cg25912611  | <i>AURKA</i>    | Aurora kinase A                                                               | 0.40 (0.098)        | 0.50 (0.065)    | -0.10 (0.118)             | 63.2        | 4.79E-07 | 20         | 54402033 (1275)                                                  |
| cg01026744  | <i>NAPIL5</i>   | Nucleosome assembly protein 1-like 5                                          | 0.68 (0.291)        | 0.58 (0.253)    | 0.10 (0.385)              | 80.4        | 9.12E-09 | 4          | 89838076 (73)                                                    |
| cg06215939  | <i>MAPK8IP3</i> | Mitogen-activated protein kinase 8 interacting protein 3                      | 0.56 (0.044)        | 0.45 (0.070)    | 0.11 (0.082)              | 73.0        | 5.01E-08 | 16         | 1695403 (819)                                                    |
| cg15298323  | <i>ACAT2</i>    | Acetyl-CoA acetyltransferase 2                                                | 0.56 (0.067)        | 0.45 (0.076)    | 0.11 (0.101)              | 79.6        | 1.1E-08  | 6          | 160102428 (647)                                                  |
| cg14893161  | <i>PM20D1</i>   | peptidase M20 domain containing 1                                             | 0.54 (0.255)        | 0.42 (0.225)    | 0.12 (0.340)              | 90.4        | 9.12E-10 | 1          | 204085874 (6)                                                    |
| cg14159672  |                 |                                                                               | 0.47 (0.294)        | 0.32 (0.234)    | 0.14 (0.375)              | 334.7       | 3.39E-34 |            | 204085802 (66)                                                   |




**Fig. 1.** Differential methylation levels expressed as % methylation for eight CpG loci (A: MAPK8IP3, B: ACAT2, C: PIWIL1, D: DEFA1, E: FAM181A, F: AURKA, G: CHFR, H: MRPL28) in peripheral blood DNA of infants born to mothers with or without asthma. The bar represents the mean of each group.

of *AURKA* methylation negatively correlated with infants height (Fig. 3D) and weight (Fig. 3E) at 12 months and with maternal hemoglobin (Fig. 3F). Methylation level of *DEFA1* was associated with infants peripheral blood neutrophils [ $r = -0.43$ ,  $P = 0.01$ ] and lymphocytes [ $r = -0.44$ ,  $P = 0.01$ ]. *FAM181A* methylation was associated with maternal ACQ score [ $r = -0.47$ ,  $P = 0.02$ ].

DISCUSSION

This study demonstrates for the first time, that maternal asthma during pregnancy is associated with epigenetic alterations in the peripheral blood of infants. There were 68 genes that were significantly differentially methylated. These genes were over enriched in biological processes

related to lipid, steroid and fatty acid metabolism and molecular functions related to enzyme inhibitor/regulator activities. There were 12 CpG loci (11 genes) that were prominent with greater than 10% change in methylation status. These loci were *FAM181A*, *MRI1*, *PIWIL1*, *CHFR*, *DEFA1*, *MRPL28*, and *AURKA*, which had increased methylation due to asthma, and *NALP1L5*, *MAP8KIP3*, *ACAT2*, and *PM20D1* which had decreased methylation in asthma. The methylation level of *PIWIL-1* was validated using the EpiTect Methyl II qPCR based methylation assay (Fig. 4).

Many of the above genes involve in key regulatory pathways concerning developmental, metabolic and inflammatory processes. In particular, we have previously reported the alterations in *DEFA1* expression in

**TABLE 4—PANTHER Biological Process and Molecular Function Categories Enriched for Positive Selection**

|                                             | Number of genes | Gene symbols                                                                                                               | P-Value* |
|---------------------------------------------|-----------------|----------------------------------------------------------------------------------------------------------------------------|----------|
| GO biological process                       |                 |                                                                                                                            |          |
| Steroid metabolic process                   | 5               | <u>CYB5R3</u> , <u>UGT2B4</u> , <i>CYP2F1</i> , <i>ACAT2</i> , <i>CYP4F11</i> , <i>ACAT2</i>                               | 0.00033  |
| Fatty acid metabolic process                | 4               | <u>CYB5R3</u> , <i>CYP2F1</i> , <u>ANXA8</u> , <i>CYP4F11</i>                                                              | 0.0034   |
| Lipid metabolic process                     | 8               | <u>CYB5R3</u> , <u>MTMR3</u> , <u>UGT2B4</u> , <i>CYP2F1</i> , <i>ACAT2</i> , <u>ANXA8</u> , <i>CYP4F11</i> , <u>CECR5</u> | 0.0035   |
| Cellular calcium ion homeostasis            | 2               | <i>ATP2B4</i> , <i>ATP2C1</i>                                                                                              | 0.0083   |
| Unsaturated fatty acid biosynthetic process | 1               | <u>CYB5R3</u>                                                                                                              | 0.018    |
| GO molecular function                       |                 |                                                                                                                            |          |
| Enzyme inhibitor activity                   | 4               | <u>CSTL1</u> , <u>SERPINF2</u> , <i>NAP1L5</i> , <u>SPINK1</u>                                                             | 0.008    |
| Peptidase inhibitor activity                | 3               | <u>CSTL1</u> , <u>SERPINF2</u> , <u>SPINK1</u>                                                                             | 0.010    |
| Enzyme regulator activity                   | 7               | <u>CSTL1</u> , <u>SERPINF2</u> , <i>NAP1L5</i> , <i>CCNT2</i> , <u>SPINK1</u> , <i>MAPK8IP3</i> , <u>ANGPT2</u>            | 0.020    |

Underlined genes indicated more methylation in asthma.  
\*One-tailed Mann–Whitney *P* value indicates the probability that selected genes within the category have *P* values for positive selection no lower than selected genes outside the category. Only the most prominent processes or molecular functions (based on  $P \leq 0.02$ ) are shown in the above table.




Fig. 2. Methylation of *FLJ32568* in infants born to mothers with asthma with and without ICS use during pregnancy (A), and atopic and non-atopic mothers with and without asthma (B) #Student's *t* test  $P < 0.05$  versus infants born to mothers with asthma who did not use ICS during pregnancy. \*ANOVA Bonferroni adjusted  $P < 0.05$  versus infants born to mothers who did not have asthma or atopy.




Fig. 3. Methylation of *MAPK8IP3* in infants is correlated with maternal blood eosinophils (A), exhaled nitric oxide (B) and total serum IgE. Methylation level of *AURKA* in infants is associated with their height (D) and weight (E), as well as maternal hemoglobin (F).




Fig. 4. Methylation of *PIWIL-1* in infants born to mothers with or without asthma as determined by EpiTect Methyl II qPCR assay.

phenotypes of asthma.<sup>19</sup> Located in chromosome 8p23.1, *DEFA1* plays a role in phagocyte-mediated host defense.<sup>20</sup> The gene is expressed predominantly in blood and bone marrow. The degree of methylation of *DEFA1* in this study also correlated with infants' lymphocyte counts and neutrophil counts. Since DNA methylation is an important epigenetic regulator of gene expression, generally increased methylation correlates with suppressed transcription. In blood, neutrophils are the major source of *DEFA1* and our previous study has shown upregulated gene expression of *DEFA1* in neutrophilic asthma compared to eosinophilic asthma in adults.<sup>19</sup> The current study has found that *DEFA1* has an increased methylation in blood of infants in the maternal asthma group, which would be expected to relate to suppression of *DEFA1* gene expression. This is likely to be related to an allergic Th2 microenvironment of the mother, however further investigation is needed regarding the role of defensins in asthma.

Certain genes from our list carry important roles in multiple cellular and inflammatory pathways. In particular *MAPK8IP3* gene, a member of MAPK pathway may be important in allergic diseases such as asthma. Located in chromosome 16p13.3, *MAPK8IP3* is an integral component of MAPK cascade, regulating MAPK/JNK signaling. There is evidence that asthma T helper 2 phenotype (allergic asthma) was associated with MAPK pathway.<sup>21</sup> Existing literature suggests MAPK signaling pathways are important in the differentiation of CD4 and CD8 T cells during thymopoiesis,<sup>21,22</sup> differentiation of eosinophils.<sup>23</sup> In addition it plays a role in regulating the functioning of T cells, eosinophils, mast cells and dendritic cells in the periphery (reviewed in Ref.<sup>24</sup>). Interestingly, we observed not only hypo-methylation of *MAP8KIP3* locus in the infants but also the level of methylation in *MAPK8IP3* was negatively correlated with maternal blood eosinophils, FeNO and Total IgE.

However we did not observe a correlation of *MAP8KIP3* locus methylation with infants' blood eosinophil count. It is likely that differential methylation of this locus may also result from maternal epigenetic modification inherited by the infant. The lack of association of *MAP8KIP3* with infants' eosinophil counts possibly due to the infants not having enough time or environmental exposure to develop measurable differences. Although biological outcomes of the hypo-methylation of this locus in infants need further investigation, the differential methylation together with correlation of the methylation with maternal clinical parameters suggests exposure effects of maternal asthma.

The locus for *CHFR* was also hypermethylated in asthma. Located in chromosome 12q24.33, *CHFR* is a ubiquitin ligase, involved in delaying mitosis (metaphase) in response to mitotic stress and in ubiquitylation of other proteins such as *AURKA*, *PLK1*<sup>25</sup> and histone deacetylase 1 (*HDAC1*),<sup>26</sup> leading to their degradation. Recent studies have shown that *CHFR* is a negative regulator of the nuclear factor- $\kappa$ B (NF- $\kappa$ B) pathway.<sup>27</sup> An important effect of this down-regulation of (NF- $\kappa$ B) is the concurrent down-regulation of interleukin *IL-8*.<sup>27</sup> *CHFR* is also known to interact with *HDAC1*, causing poly-ubiquitylation and down regulation of HDAC activity.<sup>26</sup> *CHFR* gene methylation was recently associated with persistent wheezing in children<sup>28</sup> further supporting a potential role of this gene in the development of respiratory diseases. Together, these findings suggest that regulation of this gene by gene suppression may lead to overactivity of innate cytokine pathways and development of wheezing in infants, which may predispose to the development of asthma.

The locus for *AURKA* was also significantly hypermethylated in asthma. The gene is located in chromosome 20q13, has similar functions to *CHFR*, involving many aspects of mitosis and expressed in many tissues throughout development. However *AURKA* is a serine/threonine kinase capable of phosphorylating many proteins including its own inhibitors. We report methylation of *AURKA* was correlated with infants' height, weight and average maternal hemoglobin levels during pregnancy. This would indicate that the methylation status of *AURKA* may be associated with maternal hypoxia (hemoglobin levels) and play a role in the infants' growth and development.

The hyper methylated CpG locus of *FAM181A* was among the most prominent with 16% of methylation difference in the group comparison. Localized within chromosome 14q32.12, the exact function of this gene is yet to be unveiled. A recent study indicated differential methylation of this gene in cord blood was due to maternal micronutrient supplementation.<sup>29</sup> Also the authors noted that in cord blood this gene was differentially methylated in female infants.<sup>29</sup> Our study

is the first to identify changes in methylation of *FAM181A* with maternal asthma, and its correlation with maternal ACQ score during pregnancy further indicates its potential importance in asthma.

The locus for *PIWIL1* was also hypermethylated in asthma. This gene is located in chromosome 12q24.33, and functionally attributed to many aspects of meiosis.<sup>30</sup> Although minimally expressed in normal tissues, over-expression of *PIWIL1* has been detected in many tumor types.<sup>31–33</sup> Increased expression of *PIWIL1* has been reported in asthmatic airway epithelium.<sup>34</sup> Expression of *PIWIL1* is regulated by RAS associated domain family (RASSF1C) which also regulates the MEK-ERK1/2 pathway,<sup>35</sup> known to be important in the pathogenesis of asthma.<sup>36,37</sup> We observed hyper-methylation of this locus suggesting possible down regulated expression, in contrast to the up regulation reported in the epithelium, which may relate to the tissues sampled (i.e., blood vs. airway epithelium) or the influence of developmental changes on the relationship between this gene and asthma.

The locus of *ACAT2* was also hypomethylated in our cohort of infants in association with maternal asthma. Located in chromosome 6q25.3, the product of this gene is an enzyme (acetoacetyl-CoA acetyltransferase 2) involved in lipid metabolism.<sup>38</sup> Although it had not been previously associated with asthma, the gene has been detected in blood monocytes, playing an important role in foam cell formation due to cholesterol accumulation in macrophages.<sup>39</sup> Foamy alveolar macrophages exhibit an increased pro-inflammatory function and have been associated with airway inflammation.

Considering functional aspects of the differentially methylated genes, many are known to play direct or indirect roles that are associated with immune and inflammatory processes. However functional aspects some others including *PM20D1*, *MR11* and *MRPL28* are yet to be fully investigated. Despite this, the differential methylation of *PM20D1*, a carboxypeptidase *PM20D1* precursor, is associated with maternal asthma, maternal medication use (ICS), maternal atopic status and association with maternal serum IgE may indicate an involvement of this gene in allergy and asthma. However this locus did not significantly associated with infants' clinical parameters including blood eosinophil count. These may suggest a possible maternal inheritance and the infants not having enough time or environmental exposure to develop measurable phenotypical differences. The protein is known expressed in blood plasma, suggesting a probable secretion from blood cells.

Although this is the first study of its kind investigating changes to the DNA methylation profiles of 12-month-old infants born to mothers with or without asthma, it has a number of limitations. The sample size of 40 infants may have limited our power in detecting significant methylation differences and clinical associations with DNA

methylation levels. Future studies should follow up our findings in larger cohorts. Outcomes were assessed at 12 months and attributed to effects in utero. Although most of the epigenome is re-shaped prior to birth, there are possibilities of post-natal alterations, as well as potential inheritance of differentially methylated genes from the mother,<sup>40</sup> which warrant further investigation. We assumed maternal asthma was the main effect modifier; however residual or uncontrolled confounding cannot be completely excluded. These may include maternal nutrition during pregnancy, life style, and infant breastfeeding. We used whole blood, and since each cell type has a characteristic epigenome, we essentially assessed a mixture. We have only assessed autosomal loci because of systemic differences between genders. This approach is largely suitable given the small sample size however there may be some DNA methylation differences in autosomes due to gender.<sup>41</sup> Although we assessed the validity of our findings using the EpiTect methylation profiling for the *PIWIL-1* locus, functional validation of the differentially methylated genes discovered in this study will be important in understanding their biological importance. While independent replications that address our limitations are needed, the current findings may have important and novel basis for understanding effects of maternal asthma towards the epigenome of infants.

In summary, we have identified 10 genes in which methylation statuses in infants' whole blood had significant association with maternal asthma during pregnancy. Our findings together with existing literature indicate the potential importance of these genes in the development of asthma. This study may offer guidance for the design of future studies, which may able to replicate our finding in different study populations. Follow up studies will be able to ascertain whether the methylation status of these genes are associated with the development of asthma in these infants, providing further clues to the biological mechanisms behind asthma development.

## ACKNOWLEDGEMENTS

The authors would like to thank our clinical staff involved in MAP/GIA studies for collection of samples and our laboratory staff for help in processing of those samples. We would also like to thank A/Prof. Patrick McElduff for many helpful discussions on statistics. This study was partially supported by grants from Asthma Foundation NSW, Australia and The University of Newcastle and Hunter Medical Research Institute.

## REFERENCES

1. Murphy VE, Gibson PG, Giles WB, Zakar T, Smith R, Bisits AM, Kessell CG, Clifton VL. Maternal asthma is associated with reduced female fetal growth. *Am J Respir Crit Care Med* 2003;168:1317–1323.

2. Sunyer J, Garcia-Esteban R, Castilla AM, Aurekoetxea JJ, Iniguez C, Tardon A, Espada M, Lertxundi A, Chatzi L, Rebagliato M, Kogevinas M. Exposure to second hand smoke and reproductive outcomes depending on maternal asthma. *Eur Respir J* 2012;40:371–376.
3. Carroll KN, Gebretsadik T, Griffin MR, Dupont WD, Mitchel EF, Wu P, Enriquez R, Hartert TV. Maternal asthma and maternal smoking are associated with increased risk of bronchiolitis during infancy. *Pediatrics* 2007;119:1104–1112.
4. Sawicki E, Stewart K, Wong S, Paul E, Leung L, George J. Management of asthma by pregnant women attending an Australian maternity hospital. *Aust NZ J Obstet Gynaecol* 2012;52:183–188.
5. Enriquez R, Griffin MR, Carroll KN, Wu P, Cooper WO, Gebretsadik T, Dupont WD, Mitchel EF, Hartert TV. Effect of maternal asthma and asthma control on pregnancy and perinatal outcomes. *J Allergy Clin Immunol* 2007;120:625–630.
6. Breton M-C, Beauchesne M-F, Lemiere C, Rey E, Forget A, Blais L. Risk of perinatal mortality associated with asthma during pregnancy. *Thorax* 2009;64:101–106.
7. Murphy VE, Namazy JA, Powell H, Schatz M, Chambers C, Attia J, Gibson PG. A meta-analysis of adverse perinatal outcomes in women with asthma. *Int J Obstet Gynaecol* 2011;118:1314–1323.
8. Metsala J, Kilkinen A, Kaila M, Tapanainen H, Klaukka T, Gissler M, Virtanen SM. Perinatal factors and the risk of asthma in childhood—A population-based register study in Finland. *Am J Epidemiol* 2008;168:170–178.
9. Martel M-J, Rey E, Beauchesne M-F, Malo J-L, Perreault S, Forget A, Blais L. Control and severity of asthma during pregnancy are associated with asthma incidence in offspring: two-stage case-control study. *Eur Respir J* 2009;34:579–587.
10. Scott NM, Hodyl NA, Osei-Kumah A, Stark MJ, Smith R, Clifton VL. The presence of maternal asthma during pregnancy suppresses the placental pro-inflammatory response to an immune challenge in vitro. *Placenta* 2011;32:454–461.
11. Powell H, Murphy VE, Taylor DR, Hensley MJ, McCaffery K, Giles W, Clifton VL, Gibson PG. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. *Lancet* 2011;378:983–990.
12. Powell CVE, McNamara P, Solis A, Shaw NJ. A parent completed questionnaire to describe the patterns of wheezing and other respiratory symptoms in infants and preschool children. *Arch Dis Child* 2002;87:376–379.
13. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, Gunderson KL. Genome-wide DNA methylation profiling using Infinium<sup>®</sup> assay. *Epigenomics* 2009;1:177–200.
14. Galipeau P, Chao D, Li X, Arnaudo J, Kissel H, Sanchez C, Reid B. Barrett's Esophagus and Esophageal Adenocarcinoma Epigenetic Biomarker Discovery Using Infinium Methylation. *Illumina's iCommunity Newsletter* 2008; February: [http://www.illumina.com/documents/icomunity/article\\_2008\\_2002\\_barrett.pdf](http://www.illumina.com/documents/icomunity/article_2008_2002_barrett.pdf).
15. Chudin E, Kruglyak S, Baker SC, Oeser S, Barker D, McDaniel TK. A Model of technical variation of microarray signals. *J Comput Biol* 2006;13:996–1003.
16. Naumova OY, Lee M, Kuposov R, Szyf M, Dozier M, Grigorenko EL. Differential patterns of whole-genome DNA methylation in institutionalized children and children raised by their biological parents. *Dev Psychopathol* 2012;24:143–155.
17. Mi H, Dong Q, Muruganujan A, Gaudet P, Lewis S, Thomas PD. PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. *Nucleic Acids Res* 2010;38:D204–D210.
18. Choufani S, Shapiro JS, Susiarjo M, Butcher DT, Grafodatskaya D, Lou Y, Ferreira JC, Pinto D, Scherer SW, Shaffer LG, Coullin P, Caniggia I, Beyene J, Slim R, Bartolomei MS, Weksberg R. A novel approach identifies new differentially methylated regions (DMRs) associated with imprinted genes. *Genome Res* 2011;21:465–476.
19. Baines KJ, Simpson JL, Wood LG, Scott RJ, Gibson PG. Systemic upregulation of neutrophil  $\alpha$ -defensins and serine proteases in neutrophilic asthma. *Thorax* 2011;66:942–947.
20. Wallace A, He J-Q, Burkett K, Ruan J, Connett J, Anthonisen N, Pare P, Sandford A. Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study. *Respir Res* 2006;7:76.
21. Kannan Y, Wilson S. TEC and MAPK kinase signalling pathways in T helper (TH) cell development, TH2 differentiation and allergic asthma. *J Clin Cell Immunol* 2012;S12:011.
22. Werlen G, Hausmann B, Palmer E. A motif in the [alpha][beta] T-cell receptor controls positive selection by modulating ERK activity. *Nature* 2000;406:422–426.
23. Reece P, Baatjes AJ, Cyr MM, Sehmi R, Denburg JA. Toll-like receptor mediated eosinophil-basophil differentiation: autocrine signalling by GM-CSF in cord blood hematopoietic progenitors. *Immunology* 2013;139:1365–2567.
24. Alam R, Gorska MM. Mitogen-activated protein kinase signalling and ERK1/2 bistability in asthma. *Clin Exp Allergy* 2011;41:149–159.
25. Yu X, Minter-Dykhouse K, Malureanu L, Zhao W-M, Zhang D, Merkle CJ, Ward IM, Saya H, Fang G, van Deursen J, Chen J. Chfr is required for tumor suppression and Aurora A regulation. *Nat Genet* 2005;37:401–406.
26. Oh YM, Kwon YE, Kim JM, Bae SJ, Lee BK, Yoo SJ, Chung CH, Deshaies RJ, Seol JH. Chfr is linked to tumour metastasis through the downregulation of HDAC1. *Nat Cell Biol* 2009;11:295–302.
27. Kashima L, Toyota M, Mita H, Suzuki H, Idogawa M, Ogi K, Sasaki Y, Tokino T. CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-[kappa]B. *Oncogene* 2009;28:2643–2653.
28. Morales E, Bustamante M, Vilahur N, Escaramis G, Montfort M, de Cid R, Garcia-Esteban R, Torrent M, Estivill X, Grimalt JO, Sunyer J. DNA hypomethylation at ALOX12 is associated with persistent wheezing in childhood. *Am J Respir Crit Care Med* 2012;185:937–943.
29. Khulan B, Cooper WN, Skinner BM, Bauer J, Owens S, Prentice AM, Belteki G, Constancia M, Dunger D, Affara NA. Periconceptional maternal micronutrient supplementation is associated with widespread gender related changes in the epigenome: a study of a unique resource in the Gambia. *Hum Mol Genet* 2012;21:2086–2101.
30. Xu M, You Y, Hunsicker P, Hori T, Small C, Griswold MD, Hecht NB. Mice deficient for a small cluster of Piwi-interacting RNAs implicate Piwi-interacting RNAs in transposon control. *Biol Reprod* 2008;79:51–57.
31. Taubert H, Wurl P, Greither T, Kappler M, Bache M, Bartel F, Kehlen A, Lautenschlager C, Harris LC, Kaushal D, Fussel S, Meye A, Bohnke A, Schmidt H, Holzhausen HJ, Hauptmann S. Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients. *Oncogene* 2007;26:7170–7174.
32. Liu X, Sun Y, Guo J, Ma H, Li J, Dong B, Jin G, Zhang J, Wu J, Meng L, Shou C. Expression of hiwi gene in human gastric cancer was associated with proliferation of cancer cells. *Int J Cancer* 2006;118:1922–1929.
33. Taubert H, Greither T, Kaushal D, Wurl P, Bache M, Bartel F, Kehlen A, Lautenschlager C, Harris L, Kraemer K, Meye A, Kappler M, Schmidt H, Holzhausen HJ, Hauptmann S. Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft-tissue sarcoma. *Oncogene* 2006;26:1098–1100.

34. Kicic A, Hallstrand TS, Sutanto EN, Stevens PT, Kobor MS, Taplin C, Pare PD, Beyer RP, Stick SM, Knight DA. Decreased fibronectin production significantly contributes to dysregulated repair of asthmatic epithelium. *Am J Respir Crit Care Med* 2010;181:889–898.
35. Reeves M, Baldwin M, Aragon R, Baldwin S, Chen S-T, Li X, Mohan S, Amaar Y. RASSF1C modulates the expression of a stem cell renewal gene, PIWIL1. *BMC Res Notes* 2012;5:239.
36. Goplen N, Karim Z, Guo L, Zhuang Y, Huang H, Gorska MM, Gelfand E, Pagés G, Pouysségur J, Alam R. ERK1 is important for Th2 differentiation and development of experimental asthma. *FASEB J* 2012;26:1934–1945.
37. Yoo JK, Kwon H, Khil L-Y, Zhang L, Jun H-S, Yoon J-W. IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways. *J Immunol* 2005;175:8280–8286.
38. Parini P, Davis M, Lada AT, Erickson SK, Wright TL, Gustafsson U, Sahlin S, Einarsson C, Eriksson M, Angelin B, Tomoda H, Omura S, Willingham MC, Rudel LL. ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. *Circulation* 2004;110:2017–2023.
39. Sakashita N, Miyazaki A, Chang CCY, Chang T-Y, Kiyota E, Satoh M, Komohara Y, Morganelli PM, Horiuchi S, Takeya M. Acyl-coenzyme A: cholesterol acyltransferase 2 (ACAT2) is induced in monocyte-derived macrophages: in vivo and in vitro studies. *Lab Invest* 2003;83:1569–1581.
40. Gordon L, Joo JE, Powell JE, Ollikainen M, Novakovic B, Li X, Andronikos R, Cruickshank MN, Conneely KN, Smith AK, Alisch RS, Morley R, Visscher PM, Craig JM, Saffery R. Neonatal DNA methylation profile in human twins is specified by a complex interplay between intrauterine environmental and genetic factors, subject to tissue-specific influence. *Genome Res* 2012;22:1395–1406.
41. Liu J, Morgan M, Hutchison K, Calhoun VD. A study of the influence of sex on genome wide methylation. *PLoS ONE* 2010;5:e10028.

## SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher's web-site.

# **DIFFERENTIAL DNA METHYLATION PROFILES OF INFANTS EXPOSED TO MATERNAL ASTHMA DURING PREGNANCY**

Lakshitha P Gunawardhana B. Biotech <sup>1</sup>, Katherine J Baines PhD<sup>1</sup>, Joerg Mattes MBBS, PhD<sup>1,2</sup>, Vanessa E Murphy PhD <sup>1</sup>, Jodie L Simpson PhD <sup>1</sup>, Peter G Gibson MBBS, PhD <sup>1,2,3</sup>,

<sup>1</sup>Priority Research Centre for Asthma and Respiratory Disease, Hunter Medical Research Institute, The University of Newcastle, NSW, Australia; <sup>2</sup> Department of Respiratory & Sleep Medicine, HMRI, John Hunter Hospital, New Lambton NSW, Australia; <sup>3</sup>Woolcock Institute of Medical Research, Sydney NSW, Australia.

**Corresponding author:** Katherine J Baines, Level 2 West, Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton Heights, NSW 2310, AUSTRALIA.  
Phone: (02) 40420090; Fax: (02) 40420046; Email: [katherine.baines@newcastle.edu.au](mailto:katherine.baines@newcastle.edu.au)

**Keywords:** Maternal asthma, DNA methylation, Pregnancy, CpG loci, Illumina Infinium

## **Funding:**

This study was partially supported by grants from Asthma Foundation NSW, Australia and The University of Newcastle and Hunter Medical Research Institute.

## **Conflict of Interest:**

The authors have no conflicts of interest to declare.

**Abbreviated title:** DNA methylation profiles of infants associates with maternal asthma

**E-TABLE 1: DIFFERENTIALLY EXPRESSED CpG LOCI FROM PERIPHERAL BLOOD OF INFANTS DUE TO MATERNAL ASTHMA**

| Illumina ID | Symbol   | Gene Name (HUGO)                                                              | $\beta$ mean(SD)       |                   | $\Delta\beta$ mean<br>(SD) | DiffScore | P value  |
|-------------|----------|-------------------------------------------------------------------------------|------------------------|-------------------|----------------------------|-----------|----------|
|             |          |                                                                               | Non Maternal<br>Asthma | Maternal Asthma   |                            |           |          |
| cg20022541  | FAM181A  | family with sequence similarity 181, member A                                 | 0.54 (0.288)           | 0.71 (0.241)      | -0.16<br>(0.369)           | 221.8     | 6.61E-23 |
| cg16474696  | MRI1     | methylthioribose-1-phosphate isomerase 1                                      | 0.25<br>(0.231)        | 0.41<br>(0.301)   | -0.16<br>(0.379)           | 223.6     | 4.37E-23 |
| cg13861644  | PIWIL1   | piwi-like RNA-mediated gene silencing 1                                       | 0.66<br>(0.176)        | 0.82<br>(0.111)   | -0.15<br>(0.208)           | 241.8     | 6.61E-25 |
| cg17003970  | CHFR     | checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase | 0.67<br>(0.195)        | 0.81<br>(0.036)   | -0.14<br>(0.198)           | 225.3     | 2.95E-23 |
| cg17267907  | DEFA1    | defensin, alpha 1                                                             | 0.66<br>(0.224)        | 0.77<br>(0.131)   | -0.12<br>(0.259)           | 119.3     | 1.17E-12 |
| cg12437481  | MRPL28   | mitochondrial ribosomal protein L28                                           | 0.57<br>(0.291)        | 0.68<br>(0.226)   | -0.10<br>(0.368)           | 71.0      | 7.94E-08 |
| cg25912611  | AURKA    | aurora kinase A                                                               | 0.40<br>(0.098)        | 0.50<br>(0.065)   | -0.10<br>(0.118)           | 63.2      | 4.79E-07 |
| cg26240939  | LOC57149 | hypothetical protein LOC57149                                                 | 0.66<br>(0.044)        | 0.74<br>(0.025)   | -<br>0.09(0.051)           | 57.8      | 1.66E-06 |
| cg08132711  | TMEM72   | transmembrane protein 72                                                      | 0.53<br>(0.065)        | 0.62(0.077)       | -<br>0.08(0.101)           | 41.5      | 7.08E-05 |
| cg11295113  | FOLR2    | folate receptor 2 (fetal)                                                     | 0.63<br>(0.048)        | 0.714<br>(0.029)  | -0.08<br>(0.056)           | 49.8      | 1.05E-05 |
| cg10846410  | HSPA2    | heat shock 70kDa protein 2                                                    | 0.68<br>(0.065)        | 0.7642<br>(0.030) | -0.08<br>(0.072)           | 57.8      | 1.66E-06 |

|            |         |                                                                   |                 |                   |                    |      |          |
|------------|---------|-------------------------------------------------------------------|-----------------|-------------------|--------------------|------|----------|
| cg21804950 | MTMR3   | myotubularin related protein 3                                    | 0.22<br>(0.075) | 0.30<br>(0.104)   | -0.08<br>(0.129)   | 55.3 | 2.95E-06 |
| cg14885742 | IFITM3  | interferon induced transmembrane protein 3                        | 0.42<br>(0.095) | 0.49<br>(0.110)   | -0.08<br>(0.146)   | 32.6 | 5.50E-04 |
| cg01305547 | WHSC1   | Wolf-Hirschhorn syndrome candidate 1                              | 0.62<br>(0.042) | 0.6977<br>(0.029) | -0.0753<br>(0.051) | 35.7 | 2.69E-04 |
| cg18022344 | IGSF6   | immunoglobulin superfamily, member 6                              | 0.72<br>(0.053) | 0.7918<br>(0.021) | -0.074<br>(0.057)  | 49.6 | 1.10E-05 |
| cg21061811 | DDA1    | DET1 and DDB1 associated 1                                        | 0.75<br>(0.058) | 0.82<br>(0.031)   | -0.07<br>(0.066)   | 58.7 | 1.35E-06 |
| cg09855435 | IL22RA2 | interleukin 22 receptor, alpha 2                                  | 0.72<br>(0.060) | 0.80<br>(0.012)   | -0.07<br>(0.062)   | 49.8 | 1.05E-05 |
| cg27440002 | LEAP2   | liver expressed antimicrobial peptide 2                           | 0.69<br>(0.048) | 0.76<br>(0.029)   | -0.07<br>(0.056)   | 41.8 | 6.61E-05 |
| cg21152662 | TEC     | tec protein tyrosine kinase                                       | 0.70<br>(0.042) | 0.77<br>(0.033)   | -0.07<br>(0.054)   | 44.4 | 3.63E-05 |
| cg14161241 | PLAGL1  | pleiomorphic adenoma gene-like 1                                  | 0.59<br>(0.070) | 0.67<br>(0.058)   | -0.07<br>(0.091)   | 30.7 | 8.51E-04 |
| cg16360372 | SPINK1  | serine peptidase inhibitor, Kazal type 1                          | 0.73<br>(0.065) | 0.80<br>(0.020)   | -0.07<br>(0.068)   | 49.1 | 1.23E-05 |
| cg14642338 | PAMR1   | peptidase domain containing associated with muscle regeneration 1 | 0.49<br>(0.102) | 0.56<br>(0.111)   | -0.07<br>(0.151)   | 25.7 | 2.69E-03 |
| cg05471521 | AURKA   | aurora kinase A                                                   | 0.43<br>(0.100) | 0.50<br>(0.060)   | -0.07<br>(0.117)   | 25.3 | 2.95E-03 |
| cg24272907 | RIMBP2  | RIMS binding protein 2                                            | 0.58<br>(0.058) | 0.65<br>(0.048)   | -0.07<br>(0.076)   | 28.0 | 1.58E-03 |
| cg24670715 | ANGPT2  | angiopoietin 2                                                    | 0.72<br>(0.090) | 0.79<br>(0.040)   | -0.07<br>(0.099)   | 44.7 | 3.39E-05 |
| cg15559737 | CRYBA4  | crystallin, beta A4                                               | 0.81<br>(0.054) | 0.88<br>(0.014)   | -0.07<br>(0.056)   | 79.6 | 1.10E-08 |
| cg11412582 | HERC2   | HECT and RLD domain containing E3 ubiquitin protein ligase 2      | 0.18<br>(0.062) | 0.24<br>(0.075)   | -0.07<br>(0.095)   | 44.8 | 3.31E-05 |
| cg02275359 | ZNF146  | zinc finger protein 146                                           | 0.82<br>(0.153) | 0.88<br>(0.018)   | -0.07<br>(0.154)   | 79.1 | 1.23E-08 |
| cg16174071 | ANXA8   | annexin A8                                                        | 0.76<br>(0.061) | 0.83<br>(0.031)   | -0.07<br>(0.069)   | 52.9 | 5.13E-06 |

|            |          |                                                                                                        |                 |                 |                  |      |          |
|------------|----------|--------------------------------------------------------------------------------------------------------|-----------------|-----------------|------------------|------|----------|
| cg10215079 | TAC3     | tachykinin 3                                                                                           | 0.79<br>(0.051) | 0.86<br>(0.023) | -0.07<br>(0.056) | 63.2 | 4.79E-07 |
| cg20727362 | CYB5R3   | cytochrome b5 reductase 3                                                                              | 0.78<br>(0.106) | 0.84<br>(0.042) | -0.07<br>(0.114) | 55.3 | 2.95E-06 |
| cg20359349 | FAM215A  | family with sequence similarity 215, member A (non-protein coding)                                     | 0.57<br>(0.064) | 0.64<br>(0.086) | -0.07<br>(0.107) | 23.8 | 4.17E-03 |
| cg09195271 | RNF186   | ring finger protein 186                                                                                | 0.59<br>(0.072) | 0.66<br>(0.095) | -0.07<br>(0.119) | 23.7 | 4.27E-03 |
| cg05965188 | RRP1B    | ribosomal RNA processing 1 homolog B (S. cerevisiae)                                                   | 0.78<br>(0.053) | 0.84<br>(0.025) | -0.06<br>(0.058) | 50.0 | 1.00E-05 |
| cg22815534 | CECR5    | cat eye syndrome chromosome region, candidate 5                                                        | 0.69<br>(0.053) | 0.75<br>(0.039) | -0.06<br>(0.066) | 29.6 | 1.10E-03 |
| cg20171451 | CSTL1    | cystatin-like 1                                                                                        | 0.82<br>(0.051) | 0.89<br>(0.016) | -0.06<br>(0.053) | 69.2 | 1.20E-07 |
| cg03727165 | C8orf4   | chromosome 8 open reading frame 4                                                                      | 0.62<br>(0.076) | 0.68<br>(0.080) | -0.06<br>(0.111) | 22.6 | 5.50E-03 |
| cg06673956 | GPR116   | G protein-coupled receptor 116                                                                         | 0.66<br>(0.055) | 0.72<br>(0.039) | -0.06<br>(0.067) | 25.4 | 2.88E-03 |
| cg24831427 | COQ3     | coenzyme Q3 methyltransferase                                                                          | 0.74<br>(0.073) | 0.80<br>(0.053) | -0.06<br>(0.090) | 34.8 | 3.31E-04 |
| cg17959722 | MRPL41   | mitochondrial ribosomal protein L41                                                                    | 0.12<br>(0.069) | 0.18<br>(0.108) | -0.06<br>(0.128) | 49.8 | 1.05E-05 |
| cg27563778 | C4orf17  | chromosome 4 open reading frame 17                                                                     | 0.70<br>(0.071) | 0.76<br>(0.032) | -0.06<br>(0.078) | 27.8 | 1.66E-03 |
| cg06190053 | PGM5     | phosphoglucomutase 5                                                                                   | 0.21<br>(0.073) | 0.27<br>(0.059) | -0.06<br>(0.094) | 27.8 | 1.66E-03 |
| cg04276232 | UGT2B4   | UDP glucuronosyltransferase 2 family, polypeptide B4                                                   | 0.74<br>(0.048) | 0.80<br>(0.021) | -0.06<br>(0.053) | 33.1 | 4.90E-04 |
| cg23517677 | POLR2G   | polymerase (RNA) II (DNA directed) polypeptide G                                                       | 0.78<br>(0.029) | 0.84<br>(0.020) | -0.06<br>(0.035) | 41.3 | 7.41E-05 |
| cg11822964 | PTGIR    | prostaglandin I2 (prostacyclin) receptor (IP)                                                          | 0.74<br>(0.046) | 0.80<br>(0.043) | -0.06<br>(0.062) | 32.7 | 5.37E-04 |
| cg04780454 | SERPINF2 | serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2 | 0.67<br>(0.055) | 0.73<br>(0.036) | -0.06<br>(0.066) | 23.4 | 4.57E-03 |

|            |         |                                                            |                 |                 |                 |       |          |
|------------|---------|------------------------------------------------------------|-----------------|-----------------|-----------------|-------|----------|
| cg25569462 | TRIML2  | tripartite motif family-like 2                             | 0.79<br>(0.200) | 0.73<br>(0.228) | 0.06<br>(0.303) | 32.7  | 5.37E-04 |
| cg17865752 | CCNT2   | cyclin T2                                                  | 0.18<br>(0.060) | 0.11<br>(0.035) | 0.06<br>(0.070) | 49.1  | 1.23E-05 |
| cg15287183 | PPP1R9A | protein phosphatase 1, regulatory subunit 9A               | 0.15<br>(0.077) | 0.08<br>(0.037) | 0.06<br>(0.085) | 63.3  | 4.68E-07 |
| cg18838701 | TNNI3   | troponin I type 3 (cardiac)                                | 0.33<br>(0.208) | 0.27<br>(0.144) | 0.06<br>(0.253) | 25.1  | 3.09E-03 |
| cg08752459 | CLEC2B  | C-type lectin domain family 2, member B                    | 0.16<br>(0.077) | 0.09<br>(0.034) | 0.07<br>(0.084) | 69.0  | 1.26E-07 |
| cg17408686 | CHCHD6  | coiled-coil-helix-coiled-coil-helix domain containing 6    | 0.47<br>(0.104) | 0.40<br>(0.064) | 0.07<br>(0.122) | 24.3  | 3.72E-03 |
| cg23776012 | KA222   | keratin 222                                                | 0.22<br>(0.086) | 0.15<br>(0.059) | 0.07<br>(0.104) | 49.8  | 1.05E-05 |
| cg14173969 | CD300C  | CD300c molecule                                            | 0.31<br>(0.076) | 0.24<br>(0.060) | 0.07<br>(0.096) | 34.1  | 3.89E-04 |
| cg08460435 | HENMT1  | HEN1 methyltransferase homolog 1 (Arabidopsis)             | 0.16<br>(0.067) | 0.08<br>(0.016) | 0.07<br>(0.069) | 79.1  | 1.23E-08 |
| cg06210526 | CYP2F1  | cytochrome P450, family 2, subfamily F, polypeptide 1      | 0.91<br>(0.015) | 0.84<br>(0.209) | 0.07<br>(0.210) | 334.7 | 3.39E-34 |
| cg09419670 | PSMD5   | proteasome (prosome, macropain) 26S subunit, non-ATPase, 5 | 0.36<br>(0.094) | 0.28<br>(0.139) | 0.07<br>(0.168) | 32.2  | 6.03E-04 |
| cg24655310 | CYP4F11 | cytochrome P450, family 4, subfamily F, polypeptide 11     | 0.66<br>(0.117) | 0.58<br>(0.129) | 0.07<br>(0.175) | 32.9  | 5.13E-04 |
| cg22678136 | SNRPN   | small nuclear ribonucleoprotein polypeptide N              | 0.50<br>(0.115) | 0.42<br>(0.098) | 0.08<br>(0.151) | 30.7  | 8.51E-04 |
| cg01580044 | PHTF1   | putative homeodomain transcription factor 1                | 0.35<br>(0.071) | 0.27<br>(0.040) | 0.08<br>(0.082) | 39.5  | 1.12E-04 |
| cg11997899 | DLX5    | distal-less homeobox 5                                     | 0.29<br>(0.090) | 0.21<br>(0.038) | 0.08<br>(0.098) | 49.1  | 1.23E-05 |
| cg09134747 | ATP2C1  | ATPase, Ca <sup>++</sup> transporting, type 2C, member 1   | 0.22<br>(0.093) | 0.14<br>(0.062) | 0.08<br>(0.112) | 68.4  | 1.45E-07 |
| cg22226839 | ATP2B4  | ATPase, Ca <sup>++</sup> transporting, plasma membrane 4   | 0.30<br>(0.085) | 0.21<br>(0.049) | 0.08<br>(0.098) | 55.3  | 2.95E-06 |
| cg22051636 | MRGPRX2 | MAS-related GPR, member X2                                 | 0.54<br>(0.153) | 0.46<br>(0.183) | 0.08<br>(0.239) | 39.9  | 1.02E-04 |
| cg21717724 | PSMD5   | proteasome (prosome, macropain) 26S subunit, non-ATPase, 5 | 0.74<br>(0.137) | 0.65<br>(0.178) | 0.09<br>(0.225) | 63.7  | 4.27E-07 |

|            |          |                                                          |                 |                 |                 |       |          |
|------------|----------|----------------------------------------------------------|-----------------|-----------------|-----------------|-------|----------|
| cg01026744 | NAP1L5   | nucleosome assembly protein 1-like 5                     | 0.68<br>(0.291) | 0.58<br>(0.253) | 0.10<br>(0.385) | 80.4  | 9.12E-09 |
| cg06215939 | MAPK8IP3 | mitogen-activated protein kinase 8 interacting protein 3 | 0.56<br>(0.044) | 0.45<br>(0.070) | 0.11<br>(0.082) | 73.0  | 5.01E-08 |
| cg15298323 | ACAT2    | acetyl-CoA acetyltransferase 2                           | 0.56<br>(0.067) | 0.45<br>(0.076) | 0.11<br>(0.101) | 79.6  | 1.10E-08 |
| cg14893161 | PM20D1   | peptidase M20 domain containing 1                        | 0.54<br>(0.255) | 0.42<br>(0.225) | 0.12<br>(0.340) | 90.4  | 9.12E-10 |
| cg14159672 |          |                                                          | 0.47<br>(0.294) | 0.32<br>(0.234) | 0.14<br>(0.375) | 334.7 | 3.39E-34 |